The primary efficacy endpoint is the summed pain strength difference over 1-hour.

AcelRx Pharmaceuticals initiates ARX-04 Phase 3 study in er patients with acute pain AcelRx Pharmaceuticals, Inc. , a specialty pharmaceutical organization focused on the advancement and commercialization of innovative treatments for the treating moderate-to-severe severe and breakthrough discomfort, today announced the initiation of an open-label Phase 3 study of ARX-04 for the treating adult patients who present in the emergency room with moderate-to-severe acute agony associated with trauma or damage. The primary efficacy endpoint is the summed pain strength difference over 1-hour . Basic safety endpoints, such as for example adverse events and vital signs will end up being assessed also, as will the sufferers' and healthcare companies' satisfaction with the technique of pain control.Kaiser Health Information, an unbiased news service editorially, is a scheduled plan of the Kaiser Family members Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente. , a head in the field of regenerative medicine, today announced treatment of the first individual in the 3rd dosage cohort, and seventh patient overall, in its European Phase I scientific trial for Stargardt's macular dystrophy using retinal pigment epithelial cells derived from individual embryonic stem cells . The individual was injected with 150,000 hESC-derived RPE cells, in comparison with the 100,000-cell dose found in patients of the next cohort.